Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including emerging therapeutic targets for Alzheimer’s disease (AD) and the role of the FKBP51-Hsp90 complex in underlying pathophysiological processes.
Questions
1. What are the most promising emerging therapeutic targets for AD in in vitro assays and in human cell lines? (0:05)
2. Could you tell us a little about the role of the FKBP51-Hsp90 complex in the pathophysiological processes underlying AD? (10:03)
Also see linked videos with Bengt Winblad:
Overview of the MOPEAD Project
Targeting Beta-amyloid for the Treatment of Early Alzheimer’s
Swedish Geriatric Neurologist Perspective on COVID-19
Speaker disclosure: Bengt Winblad has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
